Detailed financial statements for None (GDTC): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies.
Analysis Summary
Balance sheet quality for GDTC: current ratio of 5.2, net cash position of $1.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Revenue | 0 | 0 | 0 | $365604 | $509125 | $69501 | $319201 |
| Cost of Revenue | 0 | $4627 | $3501 | $109042 | $3736 | $17121 | $1.2M |
| Gross Profit | 0 | $54836 | $110291 | -$109042 | $505387 | $52380 | -$886564 |
| Research & Development | $439796 | $1.0M | $1.1M | $1.5M | $1.6M | $1.9M | $2.2M |
| Selling, General & Admin | $40346 | $154862 | $588459 | $596506 | $490491 | $1.3M | $1.4M |
| Operating Expenses | $651880 | $1.2M | $1.3M | $2.2M | $2.1M | $3.2M | $3.6M |
| Operating Income | -$651880 | -$1.3M | -$1.2M | -$2.3M | -$1.6M | -$3.1M | -$4.5M |
| EBITDA | -$474603 | -$1.0M | -$1.4M | -$1.5M | -$3.9M | -$2.0M | -$4.3M |
| Interest Expense | 0 | $105512 | $118392 | $122147 | $50522 | $20313 | $20571 |
| Pre-tax Income | -$858748 | -$1.9M | -$2.1M | -$3.1M | -$4.1M | -$2.6M | -$3.9M |
| Income Tax | 0 | 0 | 0 | $1599 | $653 | -$54725 | 0 |
| Net Income | -$858748 | -$1.9M | -$2.1M | -$3.1M | -$4.1M | -$2.5M | -$3.9M |
| EPS | $-0.15 | $-0.33 | $-0.30 | $-0.40 | $-0.38 | $-0.22 | $-0.33 |
| EPS (Diluted) | $-0.15 | $-0.33 | $-0.30 | $-0.40 | $-0.38 | $-0.22 | $-0.33 |
| Shares Outstanding (Diluted) | $5.6M | $5.9M | $6.9M | $7.9M | $10.6M | $11.5M | $11.6M |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Cash & Equivalents | $374424 | $887223 | $2.5M | $1.6M | $9.0M | $5.0M | $2.1M |
| Short-term Investments | $84798 | $43586 | $15267 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | $18777 | $103859 |
| Inventory | $48116 | $240971 | $432590 | $578854 | $680586 | $838640 | $1.1M |
| Total Current Assets | $549014 | $1.5M | $3.3M | $2.5M | $10.1M | $6.0M | $3.7M |
| Property, Plant & Equipment | $2.4M | $2.3M | $2.5M | $2.5M | $2.1M | $3.3M | $3.7M |
| Goodwill | $358 | $356 | $356 | $357 | $356 | $355 | $355 |
| Intangible Assets | $36000 | $44991 | $31740 | $18538 | $12090 | $92674 | $124539 |
| Total Assets | $2.9M | $3.8M | $6.1M | $5.3M | $12.4M | $10.1M | $8.0M |
| Accounts Payable | $12454 | $18956 | $46356 | $14695 | $24684 | $38623 | $124742 |
| Short-term Debt | $36127 | $2.4M | $2.7M | $3.8M | $34018 | $37641 | $40847 |
| Total Current Liabilities | $376648 | $2.7M | $2.9M | $4.2M | $718905 | $606487 | $709169 |
| Long-term Debt | $603395 | $591975 | $540379 | $471008 | $408887 | $394222 | $368656 |
| Total Liabilities | $1.0M | $3.3M | $3.5M | $4.7M | $1.1M | $1.0M | $1.1M |
| Retained Earnings | -$1.1M | -$3.0M | -$5.1M | -$8.2M | -$12.4M | -$14.8M | -$18.8M |
| Total Equity | $1.9M | $477015 | $2.6M | $589712 | $11.3M | $9.0M | $6.5M |
| Total Debt | $674609 | $3.0M | $3.3M | $4.2M | $449247 | $463147 | $482562 |
| Net Debt | $215387 | $2.1M | $732405 | $2.7M | -$8.6M | -$4.5M | -$1.6M |
| Working Capital | $172366 | -$1.3M | $346065 | -$1.7M | $9.4M | $5.4M | $3.0M |
Cash Flow (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Net Income | -$858748 | -$1.9M | -$2.1M | -$3.1M | -$4.1M | -$2.5M | -$4.0M |
| Depreciation & Amortization | $179185 | $293177 | $330648 | $394694 | $382190 | $335287 | $401584 |
| Stock-based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | $694200 |
| Change in Working Capital | -$38446 | -$162406 | -$434128 | -$145843 | -$5273 | -$79073 | -$485506 |
| Operating Cash Flow | -$640517 | -$851315 | -$1.7M | -$1.4M | -$3.5M | -$2.7M | -$3.7M |
| Capital Expenditure | -$1.2M | -$245263 | -$583715 | -$475999 | -$58454 | -$1.4M | -$703134 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | $1.2M |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$1.8M | -$1.1M | -$2.3M | -$1.9M | -$3.6M | -$4.1M | -$4.4M |
Growth & Margins (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Revenue Growth (YoY) | | | | | +39.3% | -86.3% | +359.3% |
| Net Income Growth (YoY) | | -126.2% | -6.8% | -47.3% | -35.6% | +39.3% | -55.6% |
| EPS Growth (YoY) | | -120.0% | +9.1% | -33.3% | +5.0% | +42.1% | -50.0% |
| Shares Change (YoY) | | +6.2% | +17.6% | +14.1% | +34.3% | +8.6% | +0.9% |
| FCF Growth (YoY) | | +39.9% | -109.8% | +18.2% | -91.4% | -14.2% | -7.1% |
| Gross Margin | | | | -29.8% | 99.3% | 75.4% | -277.7% |
| Operating Margin | | | | -624.5% | -310.2% | -4504.3% | -1416.0% |
| EBITDA Margin | | | | -403.1% | -763.6% | -2862.7% | -1346.0% |
| Net Margin | | | | -835.7% | -814.0% | -3621.1% | -1227.1% |
| FCF Margin | | | | -514.5% | -707.0% | -5912.5% | -1378.6% |
| Effective Tax Rate | -0.0% | -0.0% | -0.0% | -0.1% | -0.0% | 2.1% | -0.0% |
Per-Share Data (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF Per Share | $-0.33 | $-0.19 | $-0.33 | $-0.24 | $-0.34 | $-0.36 | $-0.38 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $5.6M | $5.9M | $6.9M | $7.9M | $10.6M | $11.5M | $11.6M |
Financial Health
| Piotroski F-Score | 2 |
| Altman Z-Score | 5.96 |
Key Ratios (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -35.89 | -16.02 | -17.98 | -13.41 | -17.01 | -21.10 | -5.22 |
| P/B | 15.44 | 65.35 | 14.40 | 72.00 | 6.09 | 5.98 | 3.07 |
| P/S | 0.00 | 0.00 | 0.00 | 116.14 | 134.95 | 770.82 | 62.86 |
| Gross Margin | 0.0% | 0.0% | 0.0% | -29.8% | 99.3% | 75.4% | -277.7% |
| Operating Margin | 0.0% | 0.0% | 0.0% | -624.5% | -310.2% | -4504.3% | -1416.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | -835.7% | -814.0% | -3621.1% | -1227.1% |